Fritz Offner
0000-0003-4690-3603
Publication & Citation Trends
Publications
0 total
Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7
Cited by 0
Semantic Scholar
Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety
Cited by 0
Semantic Scholar
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial.
Cited by 0
Semantic Scholar
Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial
Cited by 1
Semantic Scholar
Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update
Cited by 1
Semantic Scholar
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
Cited by 16
Semantic Scholar
Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial
Cited by 1
Semantic Scholar
Sox11-induced reprogramming of B2 cells to a B1a-like phenotype promotes Mantle Cell Lymphoma in mice
Cited by 0
Semantic Scholar
Research Topics
Lymphoma Diagnosis and Treatment
(267)
Chronic Lymphocytic Leukemia Research
(208)
CAR-T cell therapy research
(98)
Multiple Myeloma Research and Treatments
(66)
Monoclonal and Polyclonal Antibodies Research
(59)
Affiliations
Université Claude Bernard Lyon 1
Semmelweis University
Ontario Institute for Cancer Research
University College Ghent
BC Cancer Agency